Group 1 - The company has received a drug registration certificate from the National Medical Products Administration for Valsartan Amlodipine Tablets (I), which is a significant milestone in its product development [1][3]. - The drug is classified as a Class 4 chemical drug and is indicated for the treatment of primary hypertension, particularly for patients whose blood pressure is not adequately controlled with monotherapy [2][3]. - The approval of this drug enhances the company's portfolio in the antihypertensive market, potentially improving its competitive position and positively impacting future operating performance [3]. Group 2 - The drug contains 80mg of Valsartan and 5mg of Amlodipine per tablet, and the registration number is 2025S02990 [1]. - The company emphasizes strict quality control in the research, manufacturing, and sales processes of its drugs [3]. - Future market sales of the drug may be influenced by industry policy changes, procurement bidding, and market environment fluctuations, indicating some level of uncertainty [3].